Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hepion Pharmaceuticals ( (HEPA) ) just unveiled an update.
On May 26, 2025, Hepion Pharmaceuticals entered into an agreement with Panetta Partners Limited for the sale of all patent assets and related data for Rencofilstat. The agreement includes contingent value rights for Hepion’s stockholders, with potential payments tied to regulatory approval and sales milestones of the drug.
More about Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc. is a Delaware-based company operating in the pharmaceutical industry, focusing on drug development and clinical trials.
Average Trading Volume: 4,824,820
Technical Sentiment Signal: Strong Sell
Current Market Cap: $713.5K
For a thorough assessment of HEPA stock, go to TipRanks’ Stock Analysis page.